Bio-Gene Technology Management
Management criteria checks 1/4
Bio-Gene Technology's CEO is Tim Grogan, appointed in Aug 2023, has a tenure of 1.42 years. total yearly compensation is A$285.63K, comprised of 90.4% salary and 9.6% bonuses, including company stock and options. directly owns 0.03% of the company’s shares, worth A$2.56K. The average tenure of the management team and the board of directors is 1.4 years and 1.8 years respectively.
Key information
Tim Grogan
Chief executive officer
AU$285.6k
Total compensation
| CEO salary percentage | 90.4% |
| CEO tenure | 1.4yrs |
| CEO ownership | 0.03% |
| Management average tenure | 1.4yrs |
| Board average tenure | 1.8yrs |
Recent management updates
Recent updates
We're Hopeful That Bio-Gene Technology (ASX:BGT) Will Use Its Cash Wisely
Feb 22
Here's Why We're Not Too Worried About Bio-Gene Technology's (ASX:BGT) Cash Burn Situation
Oct 25Here's Why We're Not At All Concerned With Bio-Gene Technology's (ASX:BGT) Cash Burn Situation
Jun 20Bio-Gene Technology Limited (ASX:BGT) Is Expected To Breakeven In The Near Future
Apr 28What We Learned About Bio-Gene Technology's (ASX:BGT) CEO Compensation
Jan 11CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Jun 30 2024 | AU$286k | AU$258k | -AU$2m |
Compensation vs Market: Tim's total compensation ($USD176.85K) is below average for companies of similar size in the Australian market ($USD284.66K).
Compensation vs Earnings: Insufficient data to compare Tim's compensation with company performance.
CEO
Tim Grogan
1.4yrs
Tenure
AU$285,626
Compensation
Mr. Timothy Owen Grogan, LLB, B.Sc., also known as Tim, serves as Managing Director, Chief Executive Officer & Director of Bio-Gene Technology Limited since August 28, 2023. He serves as a Director of Cons...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| MD, CEO & Director | 1.4yrs | AU$285.63k | 0.030% A$ 2.6k | |
| CFO & Company Secretary | less than a year | AU$125.43k | no data | |
| Executive Director of Research & Development and Executive Director | 7yrs | AU$238.43k | 0.91% A$ 79.2k |
1.4yrs
Average Tenure
Experienced Management: BGT's management team is not considered experienced ( 1.4 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| MD, CEO & Director | 1.4yrs | AU$285.63k | 0.030% A$ 2.6k | |
| Executive Director of Research & Development and Executive Director | 9.7yrs | AU$238.43k | 0.91% A$ 79.2k | |
| Adviser to the Board | 7.1yrs | no data | no data | |
| Member of Scientific Advisory Board | 1.8yrs | AU$45.50k | 0% A$ 0 | |
| Non-Executive Director | 3.8yrs | AU$59.77k | 0.13% A$ 11.5k | |
| Member of the Scientific Advisory Board | 6.9yrs | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Non-Executive Chairman | 1.7yrs | AU$73.42k | 0.060% A$ 5.2k | |
| Non-Executive Director | 1.7yrs | AU$6.97k | 0.059% A$ 5.1k | |
| Non Executive Director | 1.3yrs | AU$52.00k | 0.059% A$ 5.1k |
1.8yrs
Average Tenure
Experienced Board: BGT's board of directors are not considered experienced ( 1.8 years average tenure), which suggests a new board.
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/03 01:56 |
| End of Day Share Price | 2024/12/30 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2024/06/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Bio-Gene Technology Limited is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Tom Waite | PAC Partners Securities Pty. Ltd. |